At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
BIA 2-093 3000 mg once dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Placebo, BIA 2-093 3000 mg once daily, and 1 other intervention for Epilepsy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
Randomized, double-blind, placebo-controlled, sequential multiple ascending dose study to determine a maximum tolerated dose
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
Primary CompletionFeb 2007
First PostedJun 2013
TodayJul 2026
First PostedJun 17, 2013
Enrollment StartDec 1, 2006
Primary CompletionFeb 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.0 years ago
Interventions
Placebodrug
Matching placebo tablets for oral administration
BIA 2-093 3000 mg once dailydrug
Eslicarbazepine acetate 600 mg tablets for oral administration
BIA 2-093 3600 mg once dailydrug
Eslicarbazepine acetate 600 mg tablets for oral administration